Fostamatinib
Sign in to save this workspacePrimary targets: SYK · FDA status: FDA Approved
Selectivity scorecard
KISS
96.74
Gini
0.613
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Fostamatinib. Strongest target: NEK9 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | NEK9 | 100.0% | 0.0% |
| 2 | EGFR | 97.8% | 2.2% |
| 3 | FLT3 | 97.2% | 2.8% |
| 4 | AURORA_A | 97.0% | 3.0% |
| 5 | ROS_ROS1 | 95.8% | 4.2% |
| 6 | MLK2_MAP3K10 | 94.2% | 5.8% |
| 7 | EPHA1 | 92.8% | 7.2% |
| 8 | EPHA4 | 91.5% | 8.5% |
| 9 | MUSK | 90.8% | 9.3% |
| 10 | JAK2 | 90.6% | 9.4% |
| 11 | EPHB1 | 90.2% | 9.8% |
| 12 | RET | 90.1% | 9.9% |
| 13 | AURORA_C | 90.0% | 10.0% |
| 14 | EPHA6 | 88.3% | 11.7% |
| 15 | EPHA2 | 87.9% | 12.1% |
| 16 | FLT4_VEGFR3 | 87.2% | 12.8% |
| 17 | ERBB2_HER2 | 87.0% | 13.0% |
| 18 | MLK1_MAP3K9 | 85.4% | 14.6% |
| 19 | MLK3_MAP3K11 | 85.1% | 14.9% |
| 20 | PYK2 | 84.9% | 15.1% |
Selectivity landscape
Where Fostamatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Fostamatinib.
Annotations
Sign in to read and post annotations.
Loading…